A cancer diagnosis brings a second crisis: the bills. BillKarma’s analysis of 6,800+ hospitals found that the same chemotherapy infusion can be billed at $4,200 at one hospital and $18,700 at another for identical drugs and identical doses. The average cancer patient faces $150,000 or more in treatment costs, and billing errors exceeding $10,000 are common. This guide explains exactly how cancer treatment is billed, where the errors hide, and how to access assistance programs that can eliminate tens of thousands in costs.

1. Types of Cancer Treatment Billing

Cancer treatment involves multiple categories of care, each billed under different code sets and by different providers. Understanding which category applies to your treatment is the first step in reviewing your bills accurately.

Chemotherapy (infusion therapy) is billed using two layers: the drug itself (using HCPCS J-codes) and the administration (using CPT codes 96413–96417 for intravenous infusion). You will typically receive a separate bill for each. The drug charge is often the largest single line item on any cancer bill.

Radiation therapy uses CPT codes in the 77xxx range. Treatment planning (77261–77263), simulation (77280–77295), and actual treatment delivery (77401–77525) are billed as distinct services. A standard course of radiation may involve 20–35 delivery sessions plus planning — each billed separately.

Immunotherapy is billed similarly to chemotherapy — J-codes for the drug, infusion administration codes for delivery. However, immunotherapy drugs (pembrolizumab, nivolumab, atezolizumab) carry acquisition costs of $10,000–$20,000 per infusion cycle, making billing accuracy critical.

Surgery for cancer (tumor resection, mastectomy, lymph node dissection) uses standard surgical CPT codes. These follow the same billing structure as any other surgery: facility fee, surgeon fee, anesthesia, and pathology.

Ongoing monitoring — blood counts (CBC), tumor markers, imaging (CT, PET scans) — runs throughout treatment and generates its own billing stream. PET scans alone cost $5,000–$11,000 each at hospital outpatient rates.

2. The Cost Breakdown

Every chemotherapy encounter typically generates four separate charges billed to your insurer simultaneously. Know what each represents so you can verify what you’re actually being charged for.

Drug cost: The acquisition cost of the chemotherapy drug. Hospitals add a markup of 100–400% above their actual acquisition price. For a drug the hospital purchased at $2,000, a $6,000–$10,000 charge to your insurer is common. Your cost-sharing is based on this inflated charge, not the acquisition cost.

Administration fee: CPT 96413 covers the first hour of intravenous infusion ($250–$600 at Medicare rates; hospitals typically charge $800–$2,500). Each additional hour is billed separately under CPT 96415. If you receive multiple drugs in the same session, each drug after the first triggers an additional administration code (96417).

Radiation planning: Before treatment delivery begins, your radiation oncologist creates a treatment plan. This involves simulation imaging, dosimetry calculations, and physician review. Planning can cost $2,000–$8,000 for a standard course of radiation and is billed once at the start of treatment.

Lab monitoring: Complete blood counts before each infusion cycle, liver function panels, and tumor marker tests add $200–$600 per visit. Over a 6-month course of treatment, cumulative lab costs reach $3,000–$6,000.

3. Common Cancer CPT and J-Codes

Code Description Medicare Rate Typical Hospital Charge
J9035 Bevacizumab (Avastin), per 10mg $69/10mg $180–$320/10mg
J9355 Trastuzumab (Herceptin), per 10mg $76/10mg $200–$390/10mg
J9999 Not otherwise classified chemo drug Varies Varies (audit carefully)
J0129 Abatacept injection, 10mg $7.90/10mg $22–$45/10mg
96413 Chemo infusion, initial up to 1 hr $148 (hospital outpatient) $800–$2,500
96415 Chemo infusion, each add’l hr $29 (hospital outpatient) $200–$600
77263 Radiation treatment planning, complex $176 $800–$2,200
77418 IMRT treatment delivery $361 $1,400–$4,500
85025 CBC with differential $11 $85–$240
71250 CT thorax with contrast $243 $3,200–$7,800
Key Takeaway 1: Compare J-code unit counts on every chemotherapy bill against your documented dose. Dosage (mg) ÷ 10 = units that should be billed. Errors in unit counts are among the most common and most expensive billing mistakes in oncology. Upload your cancer bill to BillKarma for a line-by-line review.

4. Copay Accumulator Programs

Copay accumulator programs are one of the most financially dangerous features in modern insurance plans for cancer patients. Here’s how they work and how to protect yourself.

Many cancer drug manufacturers offer copay assistance cards that cover patient cost-sharing — sometimes up to $10,000–$25,000 per year. Traditionally, the amount paid by the manufacturer’s card counted toward your deductible and out-of-pocket maximum just like cash you paid yourself.

Under a copay accumulator program, your insurer credits only the amount you personally pay toward your deductible and out-of-pocket maximum. Manufacturer assistance payments are excluded. The result: you can exhaust a $10,000 manufacturer card and find your deductible has not moved at all. When the card runs out mid-year, you suddenly owe the full cost-sharing amount from your own pocket.

How to find out if your plan uses accumulators: Call your insurer and ask directly: “Does my plan use a copay accumulator or copay maximizer program for specialty drugs?” Read your Summary of Benefits and Coverage for language about “manufacturer coupons” or “third-party payments.” Several states have passed laws restricting accumulator programs — check if your state is one of them.

Copay maximizer programs are a variation: the insurer restructures your cost-sharing to extract the maximum amount from the manufacturer assistance card over the entire year, then leave you owing nothing — but you receive no personal accumulation credit either.

5. Financial Assistance Resources

Every cancer patient should exhaust financial assistance options before paying large bills out of pocket. These programs collectively provide billions in support annually, but many patients never apply.

Manufacturer patient assistance programs (PAPs): Every major oncology drug manufacturer (Genentech, Bristol-Myers Squibb, Merck, AstraZeneca) operates a PAP for uninsured or underinsured patients. Income thresholds are often 400–600% of the federal poverty level. Apply through each manufacturer’s website or ask your oncology social worker.

CancerCare Co-Payment Assistance Foundation: Provides grants of $500–$2,000 to help with copays for specific cancer drugs. Eligibility is based on cancer type and income. Grants are available while funding lasts — apply early in treatment.

Patient Advocate Foundation Co-Pay Relief Program: Offers direct financial assistance for insurance cost-sharing, including deductibles, copays, and coinsurance. Disease-specific funds may have waiting lists, but the program serves tens of thousands of patients annually.

NeedyMeds.org: A free database of patient assistance programs, disease funds, and state pharmaceutical assistance programs. Search by drug name or diagnosis to find programs you qualify for.

Hospital charity care: If your income is below 200–400% of the federal poverty level (thresholds vary by hospital), nonprofit hospitals are required to offer free or reduced-cost care. Request a charity care application from the hospital financial counseling office. Apply before your first bill is due.

Program Who Qualifies Max Benefit How to Apply
Hospital Charity Care Income below 200–400% FPL (varies by hospital); uninsured or underinsured 100% of bill (full forgiveness at many nonprofit hospitals) Request financial counselor at hospital billing office; apply before first bill is due
Manufacturer PAPs (e.g., Genentech, BMS, Merck) Uninsured or underinsured; income typically below 400–600% FPL Free drug for duration of treatment (value: $10,000–$200,000+/year) Apply at manufacturer’s website or through oncology social worker; reapply annually
CancerCare Co-Payment Assistance Foundation Diagnosed with specific cancers; income and insurance criteria vary by fund $500–$2,000 per grant for drug copays Apply online at cancercare.org; funds available while grants last—apply early
Patient Advocate Foundation Co-Pay Relief Diagnosed with qualifying disease; income below set threshold; insured Up to $10,000/year for copays, deductibles, and coinsurance Apply at patientadvocate.org; disease-specific funds may have waitlists
NeedyMeds Any patient seeking drug or cost assistance; no income requirement to search Varies by program found (aggregates hundreds of PAPs and state funds) Search free at needymeds.org by drug name or diagnosis; no registration required
HealthWell Foundation Diagnosed with qualifying chronic or life-threatening illness; insured; income below 500% FPL Up to $10,000–$15,000/year depending on disease fund Apply at healthwellfoundation.org; check open disease funds before applying
Key Takeaway 2: Before starting any manufacturer copay assistance program, call your insurer and ask whether your plan uses a copay accumulator or maximizer. If it does, that assistance may not count toward your deductible, creating a mid-year financial crisis when the assistance card runs out. Use our out-of-pocket calculator to model your annual cancer treatment costs.

6. Reading a Chemotherapy Bill

Facility fee — hospital outpatient | $2,800
J9355 — Trastuzumab 440mg (44 units × $390) | $17,160 Medicare rate: $76/10mg = $3,344 for this dose. Hospital markup: 413%.
96413 — Chemo infusion initial 1hr | $2,100 Medicare hospital outpatient rate: $148. Charged 14x Medicare.
96415 — Chemo infusion add’l 1hr | $480
85025 — CBC (billed 3 units) | $540 Only 1 CBC was drawn this visit. Duplicate billing for 2 units ($360 overcharge).
99213 — Office visit, established patient | $220
Total Billed: $23,300 | Medicare-equivalent: $4,832 | Overcharge identified: $5,220

7. Case Studies

$12,000 Drug Billing Error Caught: Wrong Dosage Billed

A 58-year-old breast cancer patient received trastuzumab (Herceptin) every three weeks. Her oncologist prescribed 440mg per cycle based on her weight. The hospital’s billing department coded her first three infusions at 600mg (the next standard vial size), generating J9355 charges for 60 units instead of 44 units each visit.

She requested an itemized bill after her insurer sent an EOB showing charges 36% higher than she expected. Comparing the J-code unit counts against her treatment records (which specified 440mg), she identified the discrepancy. The hospital corrected all three claims, reducing charges by $12,480. Her resulting coinsurance obligation dropped by $2,496.

Lesson: Always compare J-code unit counts on your bill against the dose documented in your treatment summary. Dosage in milligrams divided by 10 should equal the number of units billed.

Key Takeaway 3: If you cannot afford your cancer treatment costs, apply for manufacturer patient assistance and hospital charity care before your first payment is due. These programs are underused — most patients who apply and qualify receive substantial help, sometimes eliminating costs entirely. Check our hospital directory to see which hospitals in your area offer charity care, what their income thresholds are, and how their overall billing transparency scores compare.

Copay Accumulator Trap: Patient Owed $8,400 More Than Expected

A lung cancer patient enrolled in a new employer plan in January. His oncologist prescribed pembrolizumab (Keytruda). The manufacturer’s copay card covered up to $25,000 per year. He assumed his $7,500 deductible would be met quickly as the card paid his cost-sharing.

In August, his copay card was exhausted. His insurer notified him that his deductible was still $0 credited — the plan used a copay accumulator program, and no manufacturer payments had counted. He owed $7,500 in deductible plus ongoing coinsurance for the rest of the year: a total of $8,400 he had not budgeted for.

Lesson: Before starting any specialty drug, call your insurer and ask explicitly whether your plan uses a copay accumulator or maximizer program. If it does, plan your cash flow accordingly and discuss alternatives with your pharmacist.

Manufacturer Assistance Saves $24,000/Year on Immunotherapy

A 64-year-old melanoma patient (not yet Medicare-eligible) was prescribed nivolumab (Opdivo) at $14,000 per infusion every four weeks. His insurance coinsurance was 20%, creating a $2,800/infusion obligation — $33,600 per year. He could not afford to continue treatment.

His oncology nurse navigator helped him apply for Bristol-Myers Squibb’s patient assistance program. He qualified based on income (under 500% FPL). The program covered his entire coinsurance obligation, reducing his annual out-of-pocket from $33,600 to under $2,400 (covering only incidental costs). He continued treatment uninterrupted for 14 months.

Lesson: Ask your oncologist’s office if they have a nurse navigator or financial counselor. These specialists know manufacturer assistance programs and can navigate the application process while you focus on treatment.

8. 340B Drug Pricing

The 340B Drug Pricing Program was created in 1992 to stretch limited federal resources for safety-net providers. It requires drug manufacturers to sell medications to qualifying hospitals and clinics at a 20–50% discount. Over 12,000 hospitals and health centers now participate.

Here is the problem for cancer patients: 340B hospitals purchase your chemotherapy drug at a steep discount but are permitted to bill your insurer — and calculate your cost-sharing — at the full market price. A drug the hospital bought for $3,000 under 340B pricing is billed at $8,000. Your 20% coinsurance is calculated on $8,000 ($1,600), not on $3,000 ($600). You pay $1,000 more per infusion because of the pricing spread.

How to find out if your hospital participates in 340B: the Health Resources and Services Administration (HRSA) maintains a public database at hrsa.gov/340b. Search your hospital by name. If it participates, your drugs may be purchased at a discount even though you’re billed at full price.

Some states are beginning to require 340B hospitals to pass discounts on to patients. Check whether your state has 340B transparency legislation in effect.

9. Clinical Trials and Cost Savings

Participating in a clinical trial can significantly reduce treatment costs. Under the Affordable Care Act, health insurers are required to cover “routine costs” of clinical trial participation for qualifying trials. This includes items that would normally be covered if you were not in a trial: office visits, lab work, standard imaging, and administration of the study drug.

The trial sponsor typically provides the investigational drug at no cost. If your standard of care would involve a $15,000/month immunotherapy drug, a clinical trial testing an equivalent drug can eliminate that cost entirely while keeping all routine care costs covered by your insurance.

Ask your oncologist whether you are eligible for any active trials. The National Cancer Institute’s trial search at cancer.gov/about-cancer/treatment/clinical-trials/search lists trials by cancer type, stage, and location.

Frequently Asked Questions

Why does chemotherapy cost so much?

Chemotherapy costs are driven by two separate charges: the drug itself (billed using J-codes) and the administration fee for the infusion. Hospitals add a facility markup on top of the drug’s acquisition cost, sometimes 200–400% above what they paid. Administration fees alone can run $300–$800 per infusion session. On top of that, labs and imaging required to monitor treatment add thousands per month.

What is a J-code on a hospital bill?

J-codes are HCPCS Level II codes used to bill injectable and infusible drugs, including most chemotherapy agents. For example, J9035 is bevacizumab (Avastin) and J9355 is trastuzumab (Herceptin). Each J-code specifies the drug and the unit of measurement (per milligram or per vial). Hospitals bill a quantity of units, so errors in unit count directly inflate your bill.

What is a copay accumulator program?

A copay accumulator program is an insurer policy that prevents manufacturer copay assistance (like drug company coupons) from counting toward your deductible or out-of-pocket maximum. You may use $6,000 in manufacturer assistance and then discover your insurer credits you $0 toward your out-of-pocket — meaning you still owe the full deductible out of your own pocket once the assistance runs out.

Can I get free cancer medication?

Yes, in many cases. Most major oncology drug manufacturers operate patient assistance programs (PAPs) that provide free or deeply discounted drugs to patients who meet income criteria, typically under 400–500% of the federal poverty level. Organizations like NeedyMeds.org and RxAssist.org maintain searchable databases. CancerCare and the Patient Advocate Foundation also offer co-pay assistance funds.

What is 340B drug pricing?

The 340B Drug Pricing Program requires pharmaceutical manufacturers to sell drugs to qualifying hospitals and clinics at a 20–50% discount. However, these hospitals are allowed to bill insurers and patients at the full market price, keeping the difference. Patients treated at 340B hospitals often pay more in cost-sharing (copays, coinsurance) because those payments are based on the full billed price, not the discounted acquisition cost.